Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 9/20 | 0.55 |
| ▸ | EPHX2 | P34913 | 8/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.46 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.46 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.46 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.46 |
| ▸ | ESRRG | P62508 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5408973 | 0.95 | NR1H4 (0.52) | NR1H4EPHX2RAB9ALMNACHRNB2 | |
| SCHEMBL5405971 | 0.95 | NR1H4 (0.54) | NR1H4EPHX2RAB9ALMNACHRNB2 | |
| SCHEMBL5416724 | 0.93 | NR1H4 (0.50) | NR1H4EPHX2RAB9ALMNACHRNB2 | |
| SCHEMBL5405685 | 0.93 | EPHX2 (0.53) | NR1H4EPHX2RAB9ALMNANPC1 | |
| SCHEMBL5405681 | 0.91 | ALDH1A1 (0.52) | NR1H4EPHX2RAB9ALMNANPC1 | |
| SCHEMBL5392424 | 0.91 | CA2 (0.54) | NR1H4EPHX2ALDH1A1 | |
| SCHEMBL5397527 | 0.91 | NR1H4 (0.54) | NR1H4EPHX2RAB9ALMNAESRRG | |
| SCHEMBL5409367 | 0.91 | LMNA (0.52) | NR1H4EPHX2RAB9ALMNACHRNB2 | |
| SCHEMBL5409780 | 0.91 | CHRNB2 (0.56) | RAB9ALMNACHRNB2CHRNB4CHRNA3 | |
| SCHEMBL5402812 | 0.90 | NR1H4 (0.47) | NR1H4EPHX2RAB9ALMNACHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7285680-B2 | β-alanine derivatives and the use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-10-23 | — | — | US | disclosed |
| US-20050256160-A1 | Beta-alanine derivatives and the use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-11-17 | — | — | US | disclosed |
| EP-1533294-A1 | BETA-ALANINE DERIVATIVE AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-05-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256160-A1 | Beta-alanine derivatives and the use thereof | TGFB1, PML, APOB | NR1H4 546/4885EPHX2 2105/4885RAB9A 3132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.